Skip to main content

Advertisement

SpringerLink
Log in

Metabolomics Approach in Allergic and Rheumatic Diseases

  • IMMUNOLOGIC/DIAGNOSTIC TESTS IN ALLERGY (JL SCHMITZ, SECTION EDITOR)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Metabolomics is the analysis of the concentration profiles of low molecular weight compounds present in biological fluids. Metabolites are nonpeptide molecules representing the end products of cellular activity. Therefore, changes in metabolite concentrations reveal the range of biochemical effects induced by a disease or its therapeutic intervention. Metabolomics has recently become feasible with the accessibility of new technologies, including mass spectrometry and high-resolution proton nuclear magnetic resonance, and has already been applied to several disorders. Indeed, it has the advantage of being a nontargeted approach for identifying potential biomarkers, which means that it does not require a preliminary knowledge of the substances to be studied. In this review, we summarize the main studies in which metabolomic approach was used in some allergic (asthma, atopic dermatitis) and rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus) to explore the feasibility of this technique as a novel diagnostic tool in these complex disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol. 2012;29:613–24.

    Article  CAS  PubMed  Google Scholar 

  2. Priori R, Scrivo R, Brandt J, Valerio M, Casadei L, Valesini G, et al. Metabolomics in rheumatic diseases: the potential of an emerging methodology for improved patient diagnosis, prognosis, and treatment efficacy. Autoimmun Rev. 2013;12:1022–30.

    Article  CAS  PubMed  Google Scholar 

  3. Goodacre R, Broadhurst D, Smilde AK, Kristal BS, Baker JD, Beger R, et al. Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics. 2007;3:231–41.

    Article  CAS  Google Scholar 

  4. Fiehn O. Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol. 2002;48:155–71.

    Article  CAS  PubMed  Google Scholar 

  5. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 2002;1:153–62.

    Article  CAS  PubMed  Google Scholar 

  6. Griffin JL. Metabolic profiles to define the genome: can we hear the phenotypes? Philos Trans R Soc Lond B Biol Sci. 2004;359:857–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Griffin JL. The Cinderella story of metabolic profiling: does metabolomics get to go the functional genomics ball? Philos Trans R Soc Lond B Biol Sci. 2006;361:147–61.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 2007;26:51–78.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Shushan B. A review of clinical diagnostic applications of liquid chromatographytandem mass spectrometry. Mass Spectrom Rev. 2010;29:930–44.

    Article  CAS  PubMed  Google Scholar 

  10. Holmes E, Antti H. Chemometric contributions to the evolution of metabonomics: mathematical solutions to characterising and interpreting complex biological NMR spectra. Analyst. 2002;127:1549–57.

    Article  CAS  PubMed  Google Scholar 

  11. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res. 2007;6:469–79.

    Article  CAS  PubMed  Google Scholar 

  12. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491:384–92.

    Article  CAS  PubMed  Google Scholar 

  13. Masoli M, Fabian D, Holt S, Beasley R, Program G. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–78.

    Article  PubMed  Google Scholar 

  14. Bisgaard H, Szefler S. Prevalence of asthma‐like symptoms in young children. Pediatr Pulmonol. 2007;42:723–8.

    Article  PubMed  Google Scholar 

  15. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360:1715–21.

    Article  PubMed  Google Scholar 

  16. Djukanović R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145:669–74.

    Article  PubMed  Google Scholar 

  17. Carraro S, Rezzi S, Reniero F, Heberger K, Giordano G, Zanconato S, et al. Metabolomics applied to exhaled breath condensate in childhood asthma. Am J Respir Crit Care Med. 2007;175:986–90.

    Article  CAS  PubMed  Google Scholar 

  18. Saude EJ, Obiefuna IP, Somorjai RL, Ajamian F, Skappak C, Ahmad T, et al. Metabolomic biomarkers in a model of asthma exacerbation urine nuclear magnetic resonance. Am J Respir Crit Care Med. 2009;179:25–34.

    Article  CAS  PubMed  Google Scholar 

  19. Saude EJ, Skappak CD, Regush S, Cook K, Ben-Zvi A, Becker A, et al. Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy. J Allergy Clin Immunol. 2011;127:757–64.

    Article  CAS  PubMed  Google Scholar 

  20. Mattarucchi E, Baraldi E, Guillou C. Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites. Biomed Chromatogr. 2011;26:89–94.

    Article  PubMed  Google Scholar 

  21. Brightling CE, Green RH, Pavord ID. Biomarkers predicting response to corticosteroid therapy in asthma. Treat Respir Med. 2005;4:309–16.

    Article  CAS  PubMed  Google Scholar 

  22. Horvath I, Barnes P, Hunt J. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26:523–48.

    Article  CAS  PubMed  Google Scholar 

  23. Carraro S, Giordano G, Reniero F, Carpi D, Stocchero M, Sterk PJ, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. Allergy. 2013;68:110–7. Provided evidence that metabolomic profiling may allow a full discrimination of asthma phenotype, suggesting that this approach may be used to develop new targeted therapies.

    Article  CAS  PubMed  Google Scholar 

  24. Ibrahim B, Marsden P, Smith JA, Custovic A, Nilsson M, Fowler SJ. Breath metabolomic profiling by nuclear magnetic resonance spectroscopy in asthma. Allergy. 2013;68:1050–6.

    Article  CAS  PubMed  Google Scholar 

  25. Canning BJ. Modeling asthma and COPD in animals: a pointless exercise? Curr Opin Pharmacol. 2003;3:244–50.

    Article  CAS  PubMed  Google Scholar 

  26. Evans CM, Fryer AD, Jacoby DB, Gleich GJ, Costello RW. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J Clin Invest. 1997;100:2254–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Gibbs NK, Tye J, Norval M. Recent advances in urocanic acid photochemistry, photobiology and photoimmunology. Photochem Photobiol Sci. 2008;7:655–67.

    Article  CAS  PubMed  Google Scholar 

  28. Ho WE, Xu YJ, Xu F, Cheng C, Peh HY, Tannenbaum SR, et al. Metabolomics reveals altered metabolic pathways in experimental asthma. Am J Respir Cell Mol Biol. 2013;48:204–11.

    Article  CAS  PubMed  Google Scholar 

  29. Jung J, Kim SH, Lee HS, Choi GS, Jung YS, Ryu DH, et al. Serum metabolomics reveals pathways and biomarkers associated with asthma pathogenesis. Clin Exp Allergy. 2013;43:425–33. Provided evidence that 1H NMR metabolomics may distinguish between adult patients with asthma and healthy subjects; the levels of serum metabolites from patients correlated with disease severity.

    Article  CAS  PubMed  Google Scholar 

  30. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483–94.

    Article  CAS  PubMed  Google Scholar 

  31. Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012;67:1475–82.

    Article  CAS  PubMed  Google Scholar 

  32. Hanifin JM. Evolving concepts of pathogenesis in atopic dermatitis and other eczemas. J Invest Dermatol. 2009;129:320–2.

    Article  CAS  PubMed  Google Scholar 

  33. Assfalg M, Bortoletti E, D'Onofrio M, Pigozzi R, Molinari H, Boner AL, et al. An exploratory (1) H-nuclear magnetic resonance metabolomics study reveals altered urine spectral profiles in infants with atopic dermatitis. Br J Dermatol. 2012;166:1123–5.

    Article  CAS  PubMed  Google Scholar 

  34. Scott DL, Wolfe F, Huizinga TWJ. Rheumatoid arthritis. Lancet. 2010;376:1094–108.

    Article  PubMed  Google Scholar 

  35. Zeidler H. The need to better classify and diagnose early and very early rheumatoid arthritis. J Rheumatol. 2012;39:212–7.

    Article  PubMed  Google Scholar 

  36. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, et al. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev. 2009;8:431–7.

    Article  CAS  PubMed  Google Scholar 

  37. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2013 Apr 9 [Epub ahead of print].

  38. Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis. 2011;70:1713–8.

    Article  CAS  PubMed  Google Scholar 

  39. Weljie AM, Dowlatabadi R, Miller BJ, Vogel HJ, Jirik FR. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. J Proteome Res. 2007;9:3456–64.

    Article  Google Scholar 

  40. Rantapää-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis. 1991;50:366–8.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Giera M, Ioan-Facsinay A, Toes R, Gao F, Dalli J, Deelder AM, et al. Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS. Biochim Biophys Acta. 2012;1821:1415–24.

    Google Scholar 

  42. van Wietmarshchen HA, Dai W, van der Kooij AJ, Reijmers TH, Schroen Y, Wang M, et al. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements. PLoS One. 2012;7:e44331.

    Article  Google Scholar 

  43. Jiang M, Xiao C, Chen G, Lu C, Zha Q, Yan X, et al. Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis. Front Med. 2011;5:219–28.

    Article  PubMed  Google Scholar 

  44. Gu Y, Lu C, Zha Q, Kong H, Lu X, Lu A, et al. Plasma metabonomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry. Mol BioSyst. 2012;8:1535–43.

    Article  CAS  PubMed  Google Scholar 

  45. Lauridsen MB, Bliddal H, Christensen R, Danneskiold-Samsøe B, Bennett R, Keun H, et al. 1H NMR spectroscopy-based interventional metabolic phenotyping: a cohort study of rheumatoid arthritis patients. J Proteome Res. 2010;9:4545–53.

    Article  CAS  PubMed  Google Scholar 

  46. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013;65:2015–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Wang Z, Chen Z, Yang S, Wang Y, Yu L, Zhang B, et al. (1)H NMR-based metabolomic analysis for identifying serum biomarkers to evaluate methotrexate treatment in patients with early rheumatoid arthritis. Exp Ther Med. 2012;4:165–71. Provided evidence that metabolic changes may predict the response to methotrexate in patients with rheumatoid arthritis.

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Kapoor SR, Filer A, Fitzpatrick MA, Fisher BA, Taylor PC, Buckley CD, et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65:1448–56. Provided evidence that metabolic changes may predict the response to biological agents in patients with rheumatoid arthritis.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Madsen RK, Lundstedt T, Gabrielsson J, Sennbro CJ, Alenius GM, Moritz T, et al. Diagnostic properties of metabolic perturbations in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R19.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Meshitsuka S, Yamazaki E, Inoue M, Hagino H, Teshima R, Yamamoto K. Nuclear magnetic resonance studies of synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Clin Chim Acta. 1999;281:163–7.

    Article  CAS  PubMed  Google Scholar 

  51. Hügle T, Kovacs H, Heijnen IA, Daikeler T, Baisch U, Hicks JM, et al. Synovial fluid metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. Clin Exp Rheumatol. 2012;30:240–5.

    PubMed  Google Scholar 

  52. Wallace D, Hahn BH. Dubois’ lupus erythematosus and related syndromes. 8th ed. Philadelphia: Sanders Elsevier; 2013.

    Google Scholar 

  53. Ouyang X, Dai Y, Wen JL, Wang LX. 1H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus. Lupus. 2011;20:1411–20.

    Article  CAS  PubMed  Google Scholar 

  54. Romick-Rosendale LE, Brunner HI, Bennett MR, Mina R, Nelson S, Petri M, et al. Identification of urinary metabolites that distinguish membranous lupus nephritis from proliferative lupus nephritis and focal segmental glomerulosclerosis. Arthritis Res Ther. 2011;13:R199.

    Article  PubMed Central  PubMed  Google Scholar 

  55. Quaggin SE, Kreidberg JA. Development of the renal glomerulus: good neighbors and good fences. Development. 2008;135:609–20.

    Article  CAS  PubMed  Google Scholar 

  56. Komatsu N, Kodama K, Yamanouchi N, Okada S, Noda S, Nawata Y, et al. Metabolic rate for glucose in systemic lupus erythematosus patients with psychiatric symptoms. Eur Neurol. 1999;42:41–8.

    Article  CAS  PubMed  Google Scholar 

  57. Alexander JJ, Zwingmann C, Quigg R. MRL/lpr mice have alterations in brain metabolism as shown with [1H-13C] NMR spectroscopy. Neurochem Int. 2005;47:143–51.

    Article  CAS  PubMed  Google Scholar 

  58. Laptook AR, Peterson J, Michael PA. Effects of lactic acid infusions and pH on cerebral blood flow and metabolism. J Cereb Blood Flow Metabol. 1988;8:193–200.

    Article  CAS  Google Scholar 

  59. Wu T, Xie C, Han J, Ye Y, Weiel J, Li Q, et al. Metabolic disturbances associated with systemic lupus erythematosus. PLoS One. 2012;7:e37210.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Ding X, Hu J, Wen C, Ding Z, Yao L, Fan Y. Rapid resolution liquid chromatography coupled with quadrupole time-of-flight mass spectrometry-based metabolomics approach to study the effects of Jieduquyuziyin prescription on systemic lupus erythematosus. PLoS One. 2014;9:e88223.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Rossana Scrivo, Luca Casadei, Mariacristina Valerio, Roberta Priori, Guido Valesini, and Cesare Manetti declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Rome, Italy

    Rossana Scrivo, Roberta Priori & Guido Valesini

  2. Dipartimento di Chimica, Sapienza Università di Roma, Piazzale Aldo Moro 5, 00185, Rome, Italy

    Luca Casadei, Mariacristina Valerio & Cesare Manetti

Authors
  1. Rossana Scrivo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Casadei
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mariacristina Valerio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Roberta Priori
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Guido Valesini
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Cesare Manetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberta Priori.

Additional information

This article is part of the Topical Collection on Immunologic/Diagnostic Tests in Allergy

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scrivo, R., Casadei, L., Valerio, M. et al. Metabolomics Approach in Allergic and Rheumatic Diseases. Curr Allergy Asthma Rep 14, 445 (2014). https://doi.org/10.1007/s11882-014-0445-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-014-0445-5

Keywords

Search

Navigation